Eris Lifesciences Ltd.'s consolidated net profit was up 29.5% in the fourth quarter of fiscal 2024, but it missed analysts' estimates.
The company posted a net profit of Rs 80 crore in the quarter-ended March, in comparison with Rs 61 crore in the year-ago period, according to an exchange filing on Tuesday. Analysts tracked by Bloomberg had estimated a profit of Rs 90 crore.
Eris Lifesciences Q4 FY24 Highlights (Consolidated, YoY)
Revenue up 36.8% to Rs 551 crore versus Rs 403 crore (Bloomberg Estimate: Rs 508 crore).
Ebitda up 25% to Rs 148 crore versus Rs 119 crore (Bloomberg Estimate: Rs 177 crore).
Margin at 27% versus 29.5% (Bloomberg Estimate: 34.90%).
Net profit up 29.5% to Rs 80 crore versus Rs 61 crore (Bloomberg Estimate: Rs 90.6 crore).
The company had other income of Rs 15 crore in Q4 as against Rs 1 crore in the same quarter last year.
Shares of Eris Lifesciences closed 1.42% higher at Rs 910 apiece, as compared with a 0.12% advance in the benchmark Nifty 50 on Tuesday.
RECOMMENDED FOR YOU
POPULAR